

## First commercial evaluation of AnteoBind NXT

Targeting first purchase agreement by early 2025

**BRISBANE, AUSTRALIA, 15 August 2024:** AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) a revenue stage company, providing solutions for the clean energy and life sciences markets using proprietary technologies, is pleased to announce the Company has commenced an evaluation of AnteoBind NXT with Indian biotech, Vidcare Innovations Private Limited (**Vidcare**), for inclusion in their range of blood diagnostic test products.

### Key Points

- **AnteoBind NXT demonstrated by Vidcare Innovations to improve particle activation being applied to Vidcare's novel and proprietary in-home test for diagnosis of hypothyroidism**
- **Vidcare detailed evaluation to confirm AnteoBind NXT provides higher specificity, improved costs and ease of manufacture compared to conventional EDC chemistry**
- **Hypothyroidism or underactive thyroid is a major health issue if left untreated - prevalent in developing countries**
- **Vidcare Innovations initiatives are aligned with the Indian Government's 'Health for All' initiative**
- **Vidcare has agreed to negotiate a supply agreement for AnteoBind NXT if the evaluations are successful – supporting their planned product launch in early 2025**

David Radford, Managing Director & Chief Executive Officer of AnteoTech commented:

*"We are excited by the data we already developed with our AnteoBind NXT product and its applicability to Vidcare's novel products which shows our superior ability to activate particles for their diagnostic tests over conventional EDC chemistry. We are therefore confident the next stage of detailed evaluation by Vidcare will support this work, by providing their in-home test an important higher specificity in diagnosing hypothyroidism. Once this evaluation is completed, we will then move to execute a purchase agreement so we can support Vidcare's planned product roll out in early 2025.*

*This is another substantial commercial opportunity for our life sciences division, given the huge medical need to better diagnose underactive thyroids in developing countries, such as India, and through the Indian Government support of Vidcare's work which is aligned with the initiative "Health for All". India is a key market for our targeted life sciences approach and this work follows on from our five-year purchase agreement with the Serum Institute of India, signed in late July."*

### First commercial evaluation of AnteoBind NXT

The Company's proprietary AnteoBind NXT was launched in 2024 due to the product's superior ability to consistently activate particles used in a range of point of care diagnostic tests, when compared to current EDC chemistry. Since engaging with Vidcare in early 2024, Vidcare has demonstrated in its laboratories that AnteoBind NXT is highly effective at activating the particles such as those in their in-home TSH test for diagnosing hypothyroidism known as Mu-sure. The current data supports increased ease of particle activation with an accelerated laboratory process. The Commercial evaluation will look at optimisation of particle specificity and a parallel reduction in antibody usage.

Vidcare will now undertake this commercial evaluation for the planned inclusion of AnteoBind NXT into their Mu-sure product and quality processes for its manufacture. This evaluation is estimated to take four to six months to complete.

This commercial evaluation is being conducted following the execution of a Memorandum of Understanding between AnteoTech and Vidcare this week (the **MOU**). Under the terms of this MOU, if the commercial evaluation achieves the designated technical hurdles, then the parties will negotiate a commercial agreement in good faith.

## About Vidcare Innovations & Hypothyroidism

Based in India, Vidcare Innovations is a leader in innovative healthcare solutions, providing portable, accurate and user-friendly diagnostic tests. Vidcare's lead product, the "Mu-sure" is an easy-to-use blood diagnostics test which comes in the form of a credit card-sized disposable chip capable of providing accurate and immediate results with no electronics or associated equipment. The "Mu-sure" kit is an in-home blood test for TSH levels or thyroid stimulating hormone to diagnose hypothyroidism.

Hypothyroidism (also called underactive thyroid) is a common condition where the thyroid doesn't create and release enough thyroid hormone into the bloodstream. While hypothyroidism is a treatable condition, if not diagnosed and left untreated, it can lead to serious health complications, including heart disease and nerve damage and in rare cases, it can be fatal. Hypothyroidism is a prevalent health concern in India and other developing countries.

The Indian Government is a supporter of Vidcare's work due to the high incidence of hypothyroidism and the major health issues including:

- **1 in 10** adult Indians are estimated to be affected by hypothyroidism
- **2 times** more cases of hypothyroidism are in India than the global average
- **1 in 2** women suffer from hypothyroidism during pregnancy leading to severe maternal, fetal and congenital complications

This announcement has been authorised for release by the Management of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** on +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

### About AnteoTech - (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

### AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.